Research shows that chronic inflammatory diseases like arthritis and inflammatory bowel disease involve a faulty immune memory where cells retain harmful inflammatory patterns. According to Gram Research analysis, scientists have identified eight druggable biological pathways that create this harmful memory, including energy metabolism, gene control, and inflammation signaling. Existing medications like colchicine, metformin, and IL-1 blockers can target these pathways, offering potential new treatment approaches that reset immune memory without completely disabling immune protection.
Your immune system can remember past infections and injuries, which normally helps protect you. But sometimes this memory goes wrong and causes chronic inflammation, leading to diseases like arthritis, heart disease, and inflammatory bowel disease. According to Gram Research analysis, scientists have discovered that this faulty immune memory uses specific biological pathways that can now be targeted with existing and new drugs. This review examines how doctors might use medications like colchicine, metformin, and others to reset this harmful immune memory and reduce long-term inflammation without completely shutting down your immune system’s ability to fight real threats.
Key Statistics
A 2026 review in Immunologic Research identified eight major biological pathways driving trained immunity in chronic inflammatory diseases, all of which are potentially druggable with existing or emerging medications.
According to a 2026 review, trained immunity contributes to harmful inflammation in at least seven chronic diseases: atherosclerosis, gout, rheumatoid arthritis, inflammatory bowel disease, neuroinflammation, chronic pain, and metabolic disease.
A 2026 analysis found that multiple existing medications including colchicine, statins, metformin, and IL-1 blockers may reset harmful immune memory by targeting trained immunity pathways.
Research reviewed in 2026 shows that trained immunity involves lasting metabolic and epigenetic changes in immune cells that can persist after infection, injury, dietary exposure, or vaccination.
The Quick Take
- What they studied: How immune cells develop a harmful ‘memory’ of past infections or injuries that causes ongoing inflammation in chronic diseases, and which drugs might fix this problem.
- Who participated: This is a review article that analyzed existing research on trained immunity and chronic inflammatory diseases. It did not involve direct patient participation but synthesized findings from numerous studies.
- Key finding: The biological pathways that create this harmful immune memory are druggable, meaning existing and new medications can target them. At least eight different drug strategies show promise for resetting this faulty memory without completely disabling immune protection.
- What it means for you: If you have a chronic inflammatory disease like rheumatoid arthritis, inflammatory bowel disease, or heart disease, future treatments might specifically target your immune system’s bad memory rather than just suppressing all inflammation. This could mean better symptom control with fewer side effects, though more research in patients is needed.
The Research Details
This is a comprehensive review article published in 2026 that examines the scientific literature on trained immunity. The authors synthesized research from multiple studies to understand how immune cells develop and maintain harmful inflammatory memories. They identified the specific biological mechanisms involved, including how cells use energy (glycolysis), how genes are turned on and off (epigenetics), and how inflammation signals are sent (IL-1 beta signaling). The review then evaluated existing drugs and experimental treatments that could target these mechanisms. Rather than conducting new experiments, the authors critically analyzed what other researchers have discovered and proposed a framework for how doctors might use this knowledge to treat patients.
Understanding the biological mechanisms of trained immunity is crucial because it explains why some chronic inflammatory diseases persist even when doctors try to suppress inflammation. By identifying the specific pathways involved, researchers can develop targeted treatments that address the root cause rather than just the symptoms. This approach could lead to more effective treatments with fewer side effects than current broad immunosuppressive drugs.
This is a review article in a peer-reviewed journal, which means experts evaluated the authors’ analysis. However, review articles synthesize existing research rather than generating new data. The strength of conclusions depends on the quality of studies reviewed. The authors acknowledge they are proposing a framework for future research and clinical practice, not reporting definitive clinical evidence. Readers should understand this represents expert interpretation of current science, not final proof that these treatments work in patients.
What the Results Show
The review identifies trained immunity as a key mechanism in chronic inflammatory diseases. Trained immunity occurs when immune cells and their precursors in bone marrow develop lasting metabolic and epigenetic changes after exposure to infections, injuries, certain lipids, crystals, dietary components, or vaccines. While this process normally helps protect against future infections, it can malfunction and cause excessive inflammation in diseases like atherosclerosis (clogged arteries), gout, rheumatoid arthritis, inflammatory bowel disease, neuroinflammation (brain inflammation), chronic pain, and metabolic disease. The authors identify eight major biological pathways that drive this harmful immune memory: glycolysis (how cells burn glucose), mTOR-HIF-1 alpha signaling (growth and oxygen sensing), the mevalonate pathway (cholesterol production), tricarboxylic acid cycle metabolites (energy production), histone methylation and acetylation (gene control), chromatin accessibility (how tightly DNA is packaged), NLRP3 inflammasome activity (inflammation trigger), and IL-1 beta signaling (inflammation messenger). Importantly, all of these pathways are druggable, meaning medications can target them.
The review evaluates specific medications that could address trained immunity. Colchicine, traditionally used for gout, appears to reduce harmful immune memory. IL-1 blockers directly target inflammation signals. Statins (cholesterol drugs) and metformin (diabetes medication) may reset metabolic pathways. mTOR inhibitors, fumarate and itaconate-related compounds, and BET/HDAC inhibitors (epigenetic drugs) can alter how genes are controlled. NLRP3 inhibitors directly block the inflammation trigger. The authors note that many of these drugs are already approved for other conditions, meaning they could potentially be repurposed for trained immunity. The significance is that doctors may not need to wait for entirely new drugs but could test existing medications in new ways.
This review builds on growing recognition in immunology that immune cells have memory beyond the well-known adaptive immune memory (antibodies and T cells). Previous research established that innate immune cells, the body’s first-line defenders, could develop lasting changes. This review synthesizes that knowledge and goes further by proposing that trained immunity is not just an interesting biological phenomenon but a practical target for drug development. It represents a shift from viewing chronic inflammatory diseases only as persistent activation states to understanding them as diseases with a memory component that can be specifically addressed.
As a review article, this work has important limitations. It does not present new clinical trial data showing these treatments work in patients with trained immunity. The framework proposed is theoretical and needs testing in human studies. The review focuses on biological mechanisms that are druggable but does not provide evidence that all proposed drugs are equally effective or safe for this purpose. Individual patient responses may vary. The authors acknowledge that their translational framework is a proposal for future research, not established clinical practice. Readers should understand this represents expert analysis of current science, not definitive clinical guidance.
The Bottom Line
Based on this review, the most promising near-term approach involves testing existing medications that target trained immunity pathways in patients with chronic inflammatory diseases. Colchicine, IL-1 blockers, and metformin have the strongest current evidence. However, these recommendations are moderate confidence because they come from a review of basic science and preliminary research, not large-scale clinical trials. Patients should not change their current treatment based on this review alone but should discuss these findings with their doctor. Future clinical trials will determine which patients benefit most from which treatments.
People with chronic inflammatory diseases including rheumatoid arthritis, inflammatory bowel disease, atherosclerosis, gout, chronic pain, and metabolic disease should be aware of this research direction. Healthcare providers treating these conditions should consider how trained immunity concepts might apply to their patients. Researchers developing new anti-inflammatory drugs should consider targeting trained immunity pathways. People without chronic inflammatory disease do not need to take action based on this review.
This is early-stage research. The biological mechanisms described have been demonstrated in laboratory and animal studies. Some drugs mentioned (like colchicine and IL-1 blockers) are already used clinically for other conditions. However, clinical trials specifically testing these drugs for trained immunity in chronic inflammatory diseases are likely still in early phases. Realistic timeline for new treatment options: 3 to 5 years for early clinical trial results, 5 to 10 years for potential new treatment approaches to become available.
Frequently Asked Questions
What is trained immunity and how does it cause chronic disease?
Trained immunity is when immune cells develop lasting metabolic and epigenetic changes that make them more reactive. While this normally helps fight infections, it can malfunction and cause excessive inflammation in diseases like arthritis, inflammatory bowel disease, and heart disease. This harmful memory persists even after the original trigger is gone.
Can existing drugs treat trained immunity in chronic inflammatory diseases?
Research suggests multiple existing drugs may target trained immunity pathways, including colchicine, metformin, statins, IL-1 blockers, and mTOR inhibitors. However, clinical trials specifically testing these drugs for trained immunity are still ongoing. Talk to your doctor about whether any might be appropriate for your condition.
How is treating trained immunity different from current inflammation treatments?
Current treatments often broadly suppress the entire immune system. Targeting trained immunity aims to reset the faulty immune memory specifically, potentially providing better symptom control with fewer side effects. This approach addresses the root cause rather than just suppressing all inflammation.
Which chronic diseases involve trained immunity?
Research indicates trained immunity contributes to atherosclerosis, gout, rheumatoid arthritis, inflammatory bowel disease, neuroinflammation, chronic pain, and metabolic disease. However, the degree to which trained immunity drives each disease varies, and more research is needed to understand individual patient differences.
When will new trained immunity treatments be available?
Some existing medications targeting trained immunity pathways are already available and being studied. Early clinical trial results may emerge within 3 to 5 years. New drugs specifically designed for trained immunity may take 5 to 10 years to develop and gain approval.
Want to Apply This Research?
- Track inflammatory markers and symptoms weekly: record joint pain (0-10 scale), fatigue level (0-10 scale), and any flare-ups. If using a medication targeting trained immunity, note any changes in frequency or severity of symptoms over 4 to 8 week periods.
- Work with your healthcare provider to identify which trained immunity pathway may be most relevant to your condition. If appropriate, discuss whether any of the mentioned medications (colchicine, metformin, IL-1 blockers, statins) might be added to your treatment plan. Use the app to track your response to any new medication.
- Establish a baseline of your current inflammation-related symptoms and disease activity. After starting any new treatment targeting trained immunity, monitor monthly for changes in symptoms, flare frequency, and overall disease burden. Share this data with your healthcare provider to assess whether the treatment is resetting your immune memory effectively.
This article summarizes a scientific review of trained immunity and potential treatments. It is not medical advice. Trained immunity research is still evolving, and most proposed treatments have not yet been formally tested in clinical trials specifically for trained immunity. Do not start, stop, or change any medications based on this article. If you have a chronic inflammatory disease, discuss these findings with your healthcare provider to determine whether any mentioned approaches might be appropriate for your individual situation. Some medications mentioned carry risks and side effects that must be weighed against potential benefits. This review represents expert analysis of current science, not definitive clinical guidance.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.